To evaluate the Season 2 (2024/ 2025) immune response of children who received nirsevimab in the 2023-2024 season (Season 1) compared to the immune response of children who did not receive nirsevimab in Season 1 and To compare the frequency and severity of illness in Season 2 between children who received nirsevimab in Season 1 to children who did not receive nirsevimab in Season 1 as assessed by Medically attended LRTI (MA LRTI) and RSV associated MA LRTI (RSV MA LRTI).
This research study wants to find out whether receiving the RSV vaccine (Beyfortus/nirsevimab) compared to not receiving it affects the body's immune response to RSV in the following respiratory season. If your child was diagnosed with RSV from November 2024-May 2025 and you are interested in participating in a 1 visit research study, please reach out for more information.
7 - 37 months of age with + RSV infection (nirsevimab recipients and non-nirsevimab recipients from the prior year)
Principal Investigator